| |
|
|
|
Registro completo
|
|
Biblioteca (s) : |
INIA La Estanzuela. |
|
Fecha : |
20/06/2022 |
|
Actualizado : |
20/06/2022 |
|
Tipo de producción científica : |
Artículos en Revistas Indexadas Internacionales |
|
Autor : |
UZAL, F.A.; GIANNITTI, F.; ASIN, J. |
|
Afiliación : |
FRANCISCO A. UZAL, California Animal Health and Food Safety, University of California-Davis, San Bernardino, CA 92408, USA.; FEDERICO GIANNITTI, INIA (Instituto Nacional de Investigación Agropecuaria), Uruguay; JAVIER ASIN, California Animal Health and Food Safety, University of California-Davis, San Bernardino, CA 92408, USA. |
|
Título : |
Yellow Lamb Disease (Clostridium perfringens Type A Enterotoxemia of Sheep): A Review. |
|
Fecha de publicación : |
2022 |
|
Fuente / Imprenta : |
Animals 2022, 12, 1590. Open Access. Doi: https://doi.org/10.3390/ani12121590 |
|
Idioma : |
Inglés |
|
Notas : |
Article history:Received: 12 May 2022 / Revised: 16 June 2022 / Accepted: 16 June 2022 / Published: 20 June 2022. |
|
Contenido : |
bstract: Yellow lamb disease is an infrequent disease in sheep for which there is scant literature, and that has been reported in the US, Australia, New Zealand, South Africa and Europe, although anecdotal evidence indicates that it may have also been diagnosed in South America. The disease is produced by some strains of Clostridium perfringens type A that produce unusually high levels of alpha- toxin. Because C. perfringens type A is ubiquitous and is found in the intestine of most clinically healthy sheep, diagnosis of yellow lamb disease is challenging and requires quantitating the amount of this microorganism present in feces and/or intestinal content. Clinically, yellow lamb disease is characterized by depression, anemia, icterus and hemoglobinuria. Occasionally, sudden death may occur. Gross findings include generalized icterus, red urine in the bladder, enlarged, pale, and friable spleen, enlarged liver with an acinar pattern, and dark, swollen kidneys. Microscopically,
yellow lamb disease is characterized by centrilobular necrosis of the liver, hemoglobinuria-associated acute tubular injury, splenic congestion, pulmonary congestion and edema. Although there are no vaccines specifically designed to prevent yellow lamb disease, several vaccines against the different types of C. perfringens may afford at least some level of protection against yellow lamb disease. |
|
Palabras claves : |
Alpha toxin; Clostridium perfringens type A; Icterus; PLATAFORMA DE SALUD ANIMAL; Yellow lamb disease. |
|
Asunto categoría : |
L73 Enfermedades de los animales |
|
URL : |
http://www.ainfo.inia.uy/digital/bitstream/item/16524/1/animals-12-01590.pdf
|
|
Marc : |
LEADER 02160naa a2200217 a 4500
001 1063332
005 2022-06-20
008 2022 bl uuuu u00u1 u #d
100 1 $aUZAL, F.A.
245 $aYellow Lamb Disease (Clostridium perfringens Type A Enterotoxemia of Sheep)$bA Review.$h[electronic resource]
260 $c2022
500 $aArticle history:Received: 12 May 2022 / Revised: 16 June 2022 / Accepted: 16 June 2022 / Published: 20 June 2022.
520 $abstract: Yellow lamb disease is an infrequent disease in sheep for which there is scant literature, and that has been reported in the US, Australia, New Zealand, South Africa and Europe, although anecdotal evidence indicates that it may have also been diagnosed in South America. The disease is produced by some strains of Clostridium perfringens type A that produce unusually high levels of alpha- toxin. Because C. perfringens type A is ubiquitous and is found in the intestine of most clinically healthy sheep, diagnosis of yellow lamb disease is challenging and requires quantitating the amount of this microorganism present in feces and/or intestinal content. Clinically, yellow lamb disease is characterized by depression, anemia, icterus and hemoglobinuria. Occasionally, sudden death may occur. Gross findings include generalized icterus, red urine in the bladder, enlarged, pale, and friable spleen, enlarged liver with an acinar pattern, and dark, swollen kidneys. Microscopically, yellow lamb disease is characterized by centrilobular necrosis of the liver, hemoglobinuria-associated acute tubular injury, splenic congestion, pulmonary congestion and edema. Although there are no vaccines specifically designed to prevent yellow lamb disease, several vaccines against the different types of C. perfringens may afford at least some level of protection against yellow lamb disease.
653 $aAlpha toxin
653 $aClostridium perfringens type A
653 $aIcterus
653 $aPLATAFORMA DE SALUD ANIMAL
653 $aYellow lamb disease
700 1 $aGIANNITTI, F.
700 1 $aASIN, J.
773 $tAnimals 2022, 12, 1590. Open Access. Doi: https://doi.org/10.3390/ani12121590
Descargar
Esconder MarcPresentar Marc Completo |
|
Registro original : |
INIA La Estanzuela (LE) |
|
|
Biblioteca
|
Identificación
|
Origen
|
Tipo / Formato
|
Clasificación
|
Cutter
|
Registro
|
Volumen
|
Estado
|
Volver
|
|
|
|
Registro completo
|
|
Biblioteca (s) : |
INIA Las Brujas. |
|
Fecha actual : |
19/04/2023 |
|
Actualizado : |
19/04/2023 |
|
Tipo de producción científica : |
Artículos en Revistas Indexadas Internacionales |
|
Circulación / Nivel : |
Internacional - -- |
|
Autor : |
BOK, M.; VEGA, C.G.; CASTELLS, M.; COLINA, R.; WIGDOROVITZ, A.; PARREÑO, V. |
|
Afiliación : |
MARINA BOK, INCUINTA, Virology Institute and Technology Innovations, National Institute of Agricultural Technology, Buenos Aires, 1686, Argentina; CONICET, Buenos Aires, C1425FQB, Argentina; Bioinnovo S.A, Buenos Aires, 1686, Argentina; CELINA G. VEGA, INCUINTA, Virology Institute and Technology Innovations, National Institute of Agricultural Technology, Buenos Aires, 1686, Argentina; CONICET, Buenos Aires, C1425FQB, Argentina; Bioinnovo S.A, Buenos Aires, 1686, Argentina; MATÍAS CASTELLS BAUER, INIA (Instituto Nacional de Investigación Agropecuaria), Uruguay; Molecular Virology Laboratory, CENUR North Litoral, Salto University Centre, University of the Republic, Salto, 50000, Uruguay; RODNEY COLINA, INIA (Instituto Nacional de Investigación Agropecuaria), Uruguay; Molecular Virology Laboratory, CENUR North Litoral, Salto University Centre, University of the Republic, Salto, 50000, Uruguay; ANDRÉS WIGDOROVITZ, INCUINTA, Virology Institute and Technology Innovations, National Institute of Agricultural Technology, Buenos Aires, 1686, Argentina; CONICET, Buenos Aires, C1425FQB, Argentina; Bioinnovo S.A, Buenos Aires, 1686, Argentina; VIVIANA PARREÑO, INCUINTA, Virology Institute and Technology Innovations, National Institute of Agricultural Technology, Buenos Aires, 1686, Argentina; CONICET, Buenos Aires, C1425FQB, Argentina; Bioinnovo S.A, Buenos Aires, 1686, Argentina. |
|
Título : |
Development of an IgY-based treatment to control bovine coronavirus diarrhea in dairy calves. |
|
Fecha de publicación : |
2023 |
|
Fuente / Imprenta : |
Viruses, 2023, volume 15, issue 3, article 708. OPEN ACCESS. doi: https://doi.org/10.3390/v15030708 |
|
ISSN : |
1999-4915 |
|
DOI : |
10.3390/v15030708 |
|
Idioma : |
Inglés |
|
Notas : |
Article history: Received 6 February 2023; Revised 5 March 2023; Accepted 6 March 2023; Published 9 March 2023. -- Academic Editor: Tomomi Takano. -- Correspondence author: Bok, M.; INCUINTA, Virology Institute and Technology Innovations, National Institute of Agricultural Technology, Buenos Aires 1686, Argentina; email:bok.marina@inta.gob.ar ; Parreño, V.; INCUINTA, Virology Institute and Technology Innovations, National Institute of Agricultural Technology, Buenos Aires, Argentina; email:parreno.viviana@inta.gob.ar -- This article belongs to the Special Issue Animal Coronaviruses: Infection, Prevention, and Antivirals https://www.mdpi.com/journal/viruses/special_issues/5XDFOYZ724 ) -- Funding: This work was supported by The National Institute of Agricultural Technology (INTA), ANPCyT from the Argentinean Agricultural Ministry (PICT Start Up 2010-1532), and Vetanco S.A. (CVT 20794). -- |
|
Contenido : |
Bovine Coronavirus (BCoV) is a major pathogen associated with neonatal calf diarrhea. Standard practice dictates that to prevent BCoV diarrhea, dams should be immunized in the last stage of pregnancy to increase BCoV-specific antibody (Ab) titers in serum and colostrum. For the prevention to be effective, calves need to suck maternal colostrum within the first six to twelve hours of life before gut closure to ensure a good level of passive immunity. The high rate of maternal Ab transfer failure resulting from this process posed the need to develop alternative local passive immunity strategies to strengthen the prevention and treatment of BCoV diarrhea. Immunoglobulin Y technology represents a promising tool to address this gap. In this study, 200 laying hens were immunized with BCoV to obtain spray-dried egg powder enriched in specific IgY Abs to BCoV on a large production scale. To ensure batch-to-batch product consistency, a potency assay was statistically validated. With a sample size of 241, the BCoV-specific IgY ELISA showed a sensitivity and specificity of 97.7% and 98.2%, respectively. ELISA IgY Abs to BCoV correlated with virus-neutralizing Ab titers (Pearson correlation, R2 = 0.92, p < 0.001). Most importantly, a pilot efficacy study in newborn calves showed a significant delay and shorter duration of BCoV-associated diarrhea and shedding in IgY-treated colostrum-deprived calves. Calves were treated with milk supplemented with egg powder (final IgY Ab titer to BCoV ELISA = 512; VN = 32) for 14 days as a passive treatment before a challenge with BCoV and were compared to calves fed milk with no supplementation. This is the first study with proof of efficacy of a product based on egg powder manufactured at a scale that successfully prevents BCoV-associated neonatal calf diarrhea. © 2023 by the authors. MenosBovine Coronavirus (BCoV) is a major pathogen associated with neonatal calf diarrhea. Standard practice dictates that to prevent BCoV diarrhea, dams should be immunized in the last stage of pregnancy to increase BCoV-specific antibody (Ab) titers in serum and colostrum. For the prevention to be effective, calves need to suck maternal colostrum within the first six to twelve hours of life before gut closure to ensure a good level of passive immunity. The high rate of maternal Ab transfer failure resulting from this process posed the need to develop alternative local passive immunity strategies to strengthen the prevention and treatment of BCoV diarrhea. Immunoglobulin Y technology represents a promising tool to address this gap. In this study, 200 laying hens were immunized with BCoV to obtain spray-dried egg powder enriched in specific IgY Abs to BCoV on a large production scale. To ensure batch-to-batch product consistency, a potency assay was statistically validated. With a sample size of 241, the BCoV-specific IgY ELISA showed a sensitivity and specificity of 97.7% and 98.2%, respectively. ELISA IgY Abs to BCoV correlated with virus-neutralizing Ab titers (Pearson correlation, R2 = 0.92, p < 0.001). Most importantly, a pilot efficacy study in newborn calves showed a significant delay and shorter duration of BCoV-associated diarrhea and shedding in IgY-treated colostrum-deprived calves. Calves were treated with milk supplemented with egg powder (final IgY Ab titer to BCoV ... Presentar Todo |
|
Palabras claves : |
Bovine coronavirus; Development; ELISA validation; IgY antibodies; Neonatal calf diarrhea. |
|
Asunto categoría : |
L20 Ecología animal |
|
URL : |
https://www.mdpi.com/1999-4915/15/3/708/pdf
|
|
Marc : |
LEADER 03567naa a2200277 a 4500
001 1064043
005 2023-04-19
008 2023 bl uuuu u00u1 u #d
022 $a1999-4915
024 7 $a10.3390/v15030708$2DOI
100 1 $aBOK, M.
245 $aDevelopment of an IgY-based treatment to control bovine coronavirus diarrhea in dairy calves.$h[electronic resource]
260 $c2023
500 $aArticle history: Received 6 February 2023; Revised 5 March 2023; Accepted 6 March 2023; Published 9 March 2023. -- Academic Editor: Tomomi Takano. -- Correspondence author: Bok, M.; INCUINTA, Virology Institute and Technology Innovations, National Institute of Agricultural Technology, Buenos Aires 1686, Argentina; email:bok.marina@inta.gob.ar ; Parreño, V.; INCUINTA, Virology Institute and Technology Innovations, National Institute of Agricultural Technology, Buenos Aires, Argentina; email:parreno.viviana@inta.gob.ar -- This article belongs to the Special Issue Animal Coronaviruses: Infection, Prevention, and Antivirals https://www.mdpi.com/journal/viruses/special_issues/5XDFOYZ724 ) -- Funding: This work was supported by The National Institute of Agricultural Technology (INTA), ANPCyT from the Argentinean Agricultural Ministry (PICT Start Up 2010-1532), and Vetanco S.A. (CVT 20794). --
520 $aBovine Coronavirus (BCoV) is a major pathogen associated with neonatal calf diarrhea. Standard practice dictates that to prevent BCoV diarrhea, dams should be immunized in the last stage of pregnancy to increase BCoV-specific antibody (Ab) titers in serum and colostrum. For the prevention to be effective, calves need to suck maternal colostrum within the first six to twelve hours of life before gut closure to ensure a good level of passive immunity. The high rate of maternal Ab transfer failure resulting from this process posed the need to develop alternative local passive immunity strategies to strengthen the prevention and treatment of BCoV diarrhea. Immunoglobulin Y technology represents a promising tool to address this gap. In this study, 200 laying hens were immunized with BCoV to obtain spray-dried egg powder enriched in specific IgY Abs to BCoV on a large production scale. To ensure batch-to-batch product consistency, a potency assay was statistically validated. With a sample size of 241, the BCoV-specific IgY ELISA showed a sensitivity and specificity of 97.7% and 98.2%, respectively. ELISA IgY Abs to BCoV correlated with virus-neutralizing Ab titers (Pearson correlation, R2 = 0.92, p < 0.001). Most importantly, a pilot efficacy study in newborn calves showed a significant delay and shorter duration of BCoV-associated diarrhea and shedding in IgY-treated colostrum-deprived calves. Calves were treated with milk supplemented with egg powder (final IgY Ab titer to BCoV ELISA = 512; VN = 32) for 14 days as a passive treatment before a challenge with BCoV and were compared to calves fed milk with no supplementation. This is the first study with proof of efficacy of a product based on egg powder manufactured at a scale that successfully prevents BCoV-associated neonatal calf diarrhea. © 2023 by the authors.
653 $aBovine coronavirus
653 $aDevelopment
653 $aELISA validation
653 $aIgY antibodies
653 $aNeonatal calf diarrhea
700 1 $aVEGA, C.G.
700 1 $aCASTELLS, M.
700 1 $aCOLINA, R.
700 1 $aWIGDOROVITZ, A.
700 1 $aPARREÑO, V.
773 $tViruses, 2023, volume 15, issue 3, article 708. OPEN ACCESS. doi: https://doi.org/10.3390/v15030708
Descargar
Esconder MarcPresentar Marc Completo |
|
Registro original : |
INIA Las Brujas (LB) |
|
|
Biblioteca
|
Identificación
|
Origen
|
Tipo / Formato
|
Clasificación
|
Cutter
|
Registro
|
Volumen
|
Estado
|
Volver
|
| Expresión de búsqueda válido. Check! |
|
|
